QLGN
Price
$4.07
Change
+$0.07 (+1.75%)
Updated
Jan 17 closing price
Capitalization
3M
SLNCF
Price
$1.50
Change
-$0.13 (-7.98%)
Updated
Jan 17 closing price
Capitalization
212.47M
Ad is loading...

QLGN vs SLNCF

Header iconQLGN vs SLNCF Comparison
Open Charts QLGN vs SLNCFBanner chart's image
Qualigen Therapeutics
Price$4.07
Change+$0.07 (+1.75%)
Volume$5K
Capitalization3M
Silence Therapeutics
Price$1.50
Change-$0.13 (-7.98%)
Volume$100
Capitalization212.47M
QLGN vs SLNCF Comparison Chart
Loading...
QLGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLNCF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
QLGN vs. SLNCF commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is QLGN is a Hold and SLNCF is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (QLGN: $4.07 vs. SLNCF: $1.50)
Brand notoriety: QLGN and SLNCF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: QLGN: 12% vs. SLNCF: 15%
Market capitalization -- QLGN: $3M vs. SLNCF: $212.47M
QLGN [@Biotechnology] is valued at $3M. SLNCF’s [@Biotechnology] market capitalization is $212.47M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

QLGN’s FA Score shows that 1 FA rating(s) are green whileSLNCF’s FA Score has 1 green FA rating(s).

  • QLGN’s FA Score: 1 green, 4 red.
  • SLNCF’s FA Score: 1 green, 4 red.
According to our system of comparison, QLGN is a better buy in the long-term than SLNCF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

QLGN’s TA Score shows that 1 TA indicator(s) are bullish while SLNCF’s TA Score has 2 bullish TA indicator(s).

  • QLGN’s TA Score: 1 bullish, 4 bearish.
  • SLNCF’s TA Score: 2 bullish, 2 bearish.
According to our system of comparison, SLNCF is a better buy in the short-term than QLGN.

Price Growth

QLGN (@Biotechnology) experienced а -4.91% price change this week, while SLNCF (@Biotechnology) price change was -8.26% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

QLGN is expected to report earnings on Mar 01, 2023.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SLNCF($212M) has a higher market cap than QLGN($3M). QLGN YTD gains are higher at: -3.325 vs. SLNCF (-42.857). QLGN has higher annual earnings (EBITDA): -6.73M vs. SLNCF (-56.89M). SLNCF has more cash in the bank: 129M vs. QLGN (388K). SLNCF has less debt than QLGN: SLNCF (139K) vs QLGN (1.43M). SLNCF has higher revenues than QLGN: SLNCF (16.2M) vs QLGN (0).
QLGNSLNCFQLGN / SLNCF
Capitalization3M212M1%
EBITDA-6.73M-56.89M12%
Gain YTD-3.325-42.8578%
P/E Ratio0.00N/A-
Revenue016.2M-
Total Cash388K129M0%
Total Debt1.43M139K1,032%
FUNDAMENTALS RATINGS
QLGN vs SLNCF: Fundamental Ratings
QLGN
SLNCF
OUTLOOK RATING
1..100
7750
VALUATION
overvalued / fair valued / undervalued
1..100
30
Undervalued
32
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
6596
P/E GROWTH RATING
1..100
42100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

QLGN's Valuation (30) in the null industry is in the same range as SLNCF (32). This means that QLGN’s stock grew similarly to SLNCF’s over the last 12 months.

QLGN's Profit vs Risk Rating (100) in the null industry is in the same range as SLNCF (100). This means that QLGN’s stock grew similarly to SLNCF’s over the last 12 months.

SLNCF's SMR Rating (98) in the null industry is in the same range as QLGN (100). This means that SLNCF’s stock grew similarly to QLGN’s over the last 12 months.

QLGN's Price Growth Rating (65) in the null industry is in the same range as SLNCF (96). This means that QLGN’s stock grew similarly to SLNCF’s over the last 12 months.

QLGN's P/E Growth Rating (42) in the null industry is somewhat better than the same rating for SLNCF (100). This means that QLGN’s stock grew somewhat faster than SLNCF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
QLGNSLNCF
RSI
ODDS (%)
N/A
Bullish Trend 12 days ago
70%
Stochastic
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 12 days ago
71%
Momentum
ODDS (%)
Bullish Trend 12 days ago
69%
Bearish Trend 12 days ago
64%
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 12 days ago
65%
TrendMonth
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 12 days ago
63%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
Bearish Trend 12 days ago
90%
N/A
BollingerBands
ODDS (%)
Bearish Trend 12 days ago
90%
Bullish Trend 12 days ago
73%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Ad is loading...
QLGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLNCF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
JBI7.600.38
+5.26%
Janus International Group
AAOI31.030.15
+0.49%
Applied Optoelectronics
ATR156.09-0.32
-0.20%
AptarGroup
SHOT0.54-0.02
-3.72%
Safety Shot
PCSA0.81-0.06
-6.59%
Processa Pharmaceuticals

QLGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, QLGN has been loosely correlated with VERU. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if QLGN jumps, then VERU could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To QLGN
1D Price
Change %
QLGN100%
+1.75%
VERU - QLGN
34%
Loosely correlated
+15.61%
PHIO - QLGN
32%
Poorly correlated
-4.81%
ZLDAF - QLGN
29%
Poorly correlated
N/A
MRNS - QLGN
28%
Poorly correlated
-0.22%
MNOV - QLGN
28%
Poorly correlated
-2.14%
More

SLNCF and

Correlation & Price change

A.I.dvisor tells us that SLNCF and ENVB have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SLNCF and ENVB's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLNCF
1D Price
Change %
SLNCF100%
-8.26%
ENVB - SLNCF
29%
Poorly correlated
+1.11%
RNXT - SLNCF
24%
Poorly correlated
+6.38%
QLGN - SLNCF
21%
Poorly correlated
+1.75%
SOLTF - SLNCF
9%
Poorly correlated
N/A
PVCT - SLNCF
8%
Poorly correlated
-2.35%
More